期刊文献+

终末期肾脏病患者血清脂联素水平及与炎症因子的相关性研究

Serum adiponectin levels and inflammatory markers in patients with end-stage renal disease
原文传递
导出
摘要 目的检测终末期肾脏病(ESRD)患者血清脂联素(ADPN)、肿瘤坏死因子-α(TNF—α)、超敏C反应蛋白(hs—CRP)及肾功能水平,探讨ESRD患者血清ADPN水平的变化及与炎症因子的关系。方法选择ESRD患者60例,分为3组:肾衰非透析组(18例)、血液透析组(22例)和腹膜透析组(20例)。另设健康对照组(20例)。用ELISA方法检测血清ADPN、TNF—α和hs—CRP。比较各组间的差别。结果ESRD患者血清ADPN水平在肾衰非透析组[(15.88±4.94)mg/L]、血液透析组[(14.26±4.54)mg/L]和腹膜透析组[(14.55±3.51)mg/L]均显著升高(与对照组[(4.95±2.19)mg/L]相比,P〈0.01),但非透析和透析各组之间的差异无统计学意义(P〉0.05)。ESRD患者的血清TNF—α和hs—CRP水平在透析和非透析各组亦显著升高(与对照组相比,P〈0.01),并且在透析患者显著高于非透析患者(P〈0.01)。ESRD患者的血清ADPN水平与TNF—α呈正相关(r≥0.478,P〈0.01),与肾小球滤过率呈负相关(r≥-0.582,P〈0.01)。结论ESRD患者的血清ADPN水平明显升高,并与TNF—α、肾小球滤过率等因素有关。 Objective To examine the levels of serum adiponectin (ADPN)in patients with end-stage renal disease (ESRD), and identify the relationship between serum ADPN and tumor necrosis factor (TNF)-α, high sensitivity C-reactive protein (hs-CRP) and renal function. Methods Sixty ESRD patients and twenty normal healthy persons were involved in this study. The patients were divided into three groups: patients with chronic renal failure (CRF, 18 cases), patients with hemodia]ysis (HD,22 cases) and patients with peritoneal dialysis ( PD,20 eases). The levels of serum ADPN, TNF-α and hs-CRP were detected by means of ELISA. Differences in continuous variables between the three groups were evaluated. Results The levels of serum ADPN, TNF-α and hs-CRP in CRF, HD and PD patients were significantly higher than those in control group ( P 〈0. 01 ). Serum ADPN levels in ESRD patients were positive related to serum TNF-α( r ≥ 0. 478, P 〈 0. 01 ), and negative related to GFR ( r ≥ - 0. 582, P 〈 0. 01 ). Conclusion The level of serum ADPN was markedly increased in patients with ESRD, and correlated with serum TNF-α level and.renal function.
出处 《中国医师杂志》 CAS 2008年第10期1348-1350,共3页 Journal of Chinese Physician
基金 广东省珠海市科技局科技计划资助项目(PC20052029) 广东省科技厅科技计划资助项目(2008D030301084)
关键词 肾功能衰竭 慢性 胞间信号肽类和蛋白质类 C反应蛋白质 肿瘤坏死因子 肾功能试验 Kidney failure, chronic Intercellular signaling peptides and proteins C-reactive protein Tumor necrosis factor Kidney function tests
  • 相关文献

参考文献11

  • 1Axelsson J, Heimburger O, Stenvinkel P. Adipose tissue and inflammation in chronic kidney disease. Contrib Nephrol,2006,151 : 165- 174.
  • 2Barazzoni R, Biolo G, Zanetti M, et al. Inflammation and adipose tissue in uremia. J Ren Nutr, 2006,16 ( 3 ) : 204 -207.
  • 3郭军利,张桦.慢性肾脏病胰岛素抵抗的研究进展[J].国际内科学杂志,2007,34(3):170-173. 被引量:2
  • 4郭军利,贾宁,张桦,张慧涛,周文英.早期慢性肾脏病患者血清脂联素水平的变化[J].中国医师杂志,2008,10(7):871-873. 被引量:1
  • 5Diez J J, Iglesias P, Fernandez-Reyes M J, et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol, 2005,62 ( 2 ) : 242 -249.
  • 6Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol, 2002,13( 1 ) :134-141.
  • 7Huang JW,Yen CJ,ehiang HW, et al. Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis, 2004,43 (6) : 1047-1055.
  • 8Menon V,Li L,Wang X, et al. Adiponetin and mortality in patients with chronic kidney disease. J Am Soc Nephrol,2006,17 (9) :2599-2606.
  • 9Yaturu S, Reddy RD, Rains J, et al. Plasma and urine levels of resistin and adiponectin in chronic kidney disease. Cytokine,2007,37( 1 ) :1-5.
  • 10Iwashima Y, Horio T, Kumada M, et al. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol, 2006,98(12) :1603-1608.

二级参考文献33

  • 1张桦,金石昆,林琳,邹和群.IgA肾病患者的胰岛素抵抗与代谢综合征[J].临床肾脏病杂志,2004,4(4):149-152. 被引量:1
  • 2Kobayashi S, Maesato K, Moriya H, et al. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis,2005,45(2) :275-280.
  • 3Diez JJ, Iglesias P, Fernandez-Reyes M J, et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascu- lar disease in patients with end-stage renal disease. Clin Endocrinol, 2005,62(2) :242-249.
  • 4Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol,2002,13 : 134-141.
  • 5Huang JW,Yen CJ,Chiang HW, et al. Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis ,2004,43 ( 6 ) : 1047-1055.
  • 6Marchlewska A, Stenvinkel P, Lindholm B, et al. Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. Kidney Int, 2004,66:46-50.
  • 7Menon V, Li L, Wang X,et al. Adiponetin and mortality in patients with chronic kidney disease. J Am Soc Nephrol,2006,17 (9) :2599-2606.
  • 8Guebre-Egziabher F, Bernhard J, Funahashi T, et al. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant,2004,20( 1 ) :129-134.
  • 9Zoccali C, Mallamaci F, Panuccio V, et al. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int, 2003, 84(Suppl) : 98-102.
  • 10Risch L,Saely C, Hoefle G,et al. Relationship between glomerular filtration rate and the adiponectin ,resistin and leptin in coronary patients with predominantly normal or mildly impaird renal function. Clin Chim Acta,2007,376 ( 1-2 ) : 108 -113.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部